Organogenesis Holdings Inc. reported a net product revenue of $100.8 million for the second quarter of 2025, a 23% decrease year-over-year. The company experienced a net loss of $9.4 million, which was an improvement from the $17.0 million net loss in the same period last year. Advanced Wound Care product revenue decreased significantly, while Surgical & Sports Medicine products saw an increase.

Organogenesis Holdings Inc. reported a net revenue of $86.7 million for the first quarter of 2025, a 21% decrease from $110.0 million in the prior year. The company experienced a net loss of $18.8 million, a significant increase from a net loss of $2.1 million in the first quarter of 2024. This decline was primarily driven by a 23% decrease in Advanced Wound Care product revenue.

Organogenesis Holdings Inc. announced a robust fourth quarter for 2024, with net revenue reaching $126.7 million, a 27% increase from Q4 2023. The company also reported a net income of $7.7 million, a substantial improvement from a net loss in the prior year, and Adjusted EBITDA of $18.2 million, marking a 143% increase.

Organogenesis Holdings Inc. reported a net revenue of $115.2 million for Q3 2024, a 6% increase compared to Q3 2023. Net income increased by $9.1 million to $12.3 million. The company updated its revenue guidance for the year ending December 31, 2024, expecting net revenue between $455.0 million and $480.0 million.

Organogenesis Holdings Inc. reported second quarter 2024 financial results with net revenue of $130.2 million, an increase of $12.9 million compared to the second quarter of 2023. However, the company reported a net loss of $17.0 million, compared to net income of $5.3 million for the second quarter of 2023.

Organogenesis Holdings Inc. reported a strong start to 2024, with first quarter revenue exceeding the high-end of revenue guidance. Net revenue increased by $2.3 million compared to the first quarter of 2023. The company is reaffirming its prior guidance for fiscal year 2024.

Organogenesis Holdings Inc. reported a net revenue of $99.7 million for Q4 2023, a 14% decrease compared to Q4 2022. The company experienced a net loss of $0.6 million, contrasting with a net income of $7.5 million in the same quarter of the previous year. Despite challenges, Organogenesis is implementing commercial support programs and anticipates a return to revenue growth through customer value demonstration and new product launches.

Organogenesis Holdings Inc. reported a decrease in net revenue for Q3 2023, with $108.5 million compared to $116.9 million in Q3 2022. However, the company saw improvements in operating profitability and generated strong adjusted EBITDA and cash flow compared to the prior year period. Net income increased to $3.2 million from $0.2 million year-over-year.

Organogenesis Holdings Inc. reported second quarter 2023 financial results with a decrease in net revenue to $117.3 million compared to $121.4 million for the second quarter of 2022. Net income also decreased to $5.3 million from $8.7 million in the prior year. The company withdrew its fiscal year 2023 guidance due to uncertainties from recent local coverage determinations.

Organogenesis Holdings Inc. reported a net revenue increase of 11% to $107.6 million for Q1 2023, driven by Advanced Wound Care products, which increased by 12%. However, the company experienced a net loss of $3.0 million, compared to a net loss of $0.9 million in Q1 2022.

Organogenesis Holdings Inc. reported a decrease in net revenue and net income for the fourth quarter of 2022 compared to the same period in 2021. Net revenue decreased by 10% to $115.5 million, and net income decreased significantly to $7.5 million.

Organogenesis Holdings Inc. reported a 3% increase in net revenue for Q3 2022, reaching $116.9 million compared to $113.8 million in Q3 2021. However, net income decreased to $0.2 million from $12.6 million, and adjusted EBITDA decreased to $11.6 million from $21.7 million in the same period.

Organogenesis reported a slight decrease in net revenue for Q2 2022, with a marginal decline of 1% compared to Q2 2021. Despite the revenue decrease, the company's gross profit increased by 2%. However, net income and adjusted EBITDA experienced significant decreases of 58% and 26%, respectively, compared to the previous year.

Organogenesis Holdings Inc. reported a 4% decrease in net revenue for Q1 2022, totaling $98.1 million compared to $102.6 million in Q1 2021. Net income also decreased to $0.1 million from $9.9 million in the same period last year. The company's Advanced Wound Care segment saw a slight increase in revenue, while the Surgical & Sports Medicine segment experienced a significant decrease.

Organogenesis Holdings Inc. reported a 20% increase in net revenue for Q4 2021 compared to Q4 2020. Net income also increased significantly, and the company provided financial guidance for fiscal year 2022.

Organogenesis Holdings Inc. reported a 13% increase in net revenue for the third quarter of 2021, reaching $113.8 million. Net income was $12.6 million, and adjusted EBITDA was $21.7 million. The company reaffirmed its full-year revenue guidance.

Organogenesis Holdings Inc. reported a 79% increase in net revenue for the second quarter of 2021, reaching $123.2 million, compared to $69 million in the same period of 2020. The company also achieved a net income of $20.7 million, a significant improvement from the net loss of $5.2 million in the second quarter of 2020.

Organogenesis Holdings Inc. reported a strong first quarter in 2021, with net revenue increasing by 66% to $102.6 million compared to the first quarter of 2020. The company also saw a significant increase in net income, reporting $9.9 million compared to a net loss of $16.3 million in the same period last year.

Organogenesis Holdings Inc. reported a strong fourth quarter with a 43% increase in net revenue compared to the same period last year. Net income increased by $22.9 million, and adjusted EBITDA saw a significant rise of $24.1 million.

Organogenesis Holdings Inc. reported a 57% increase in net revenue for Q3 2020, reaching $100.8 million compared to $64.3 million in Q3 2019. The company also saw a net income of $20.9 million, a significant turnaround from the net loss of $10.7 million in the same quarter of the previous year. The growth was driven by strong performance in both Advanced Wound Care and Surgical & Sports Medicine product categories.

Organogenesis Holdings Inc. reported a 6% increase in net revenue for Q2 2020, reaching $69.0 million, driven by strong performance in Advanced Wound Care products. The company also reduced its net loss to $5.2 million and achieved positive Adjusted EBITDA of $274 thousand.

Organogenesis Holdings Inc. reported an 8% increase in net revenue for the first quarter of 2020, reaching $61.7 million compared to $57.1 million in the first quarter of 2019. The company experienced a net loss of $16.3 million, slightly higher than the $15.7 million loss in the same period last year. The increase in revenue was driven by growth in both Advanced Wound Care and Surgical & Sports Medicine products.

Organogenesis Holdings Inc. reported a 17% increase in net revenue for Q4 2019, reaching $74.6 million compared to $63.6 million in Q4 2018. The company's net loss decreased to $4.4 million from $9.3 million in the same period last year, and Adjusted EBITDA income was $0.8 million, a significant improvement from the $0.1 million loss in Q4 2018.